Cyprotex Share Discussion Threads

[buywell2] 13/12/2010 00:58

Global Markets for In Vitro Toxicity Testing
BCC Research
September 1, 2010
168 Pages - Pub ID: WA2830385
US $4,850.00 Online Download US $4,850.00 Hard Copy Mail Delivery US $8,500.00 Global Site License
Abstract

Table of
Contents Related Reports





Countries covered: Global

The global in vitro toxicity (predictive toxicity) testing market is valued at more than $1.3 billion in 2010. With heightened awareness of animal welfare in laboratory research testing, the in vitro toxicity testing market has an anticipated value of $2.7 billion in 2015, a compound annual growth rate (CAGR) of 15% between 2010 and 2015.

The largest market sector is currently the cosmetics and personal-care industry, which accounts for a market share of more than 50%. This sector is currently valued at $702 million and is expected to reach $1.3 billion by 2015, a compound annual growth rate (CAGR) of 13.1%.

The pharmaceuticals segment is one of the most significant with a 32% market share valued at $424 million in 2010. By 2015, this sector is projected to reach a value of $976 million, a compound annual growth rate (CAGR) of 18.2%.



Additional Information

INTRODUCTION

STUDY GOALS AND OBJECTIVES

BCC's goal in conducting this study was to determine the current status of the global in vitro toxicity testing market and assess its growth potential over the 5-year period from 2010 to 2015. We were particularly interested in understanding the current market scenario for alternative measures to animal testing.

Predictive toxicology is often cross-referenced with in vitro methods. This report assesses the growth and market potential for these methods. In addition, we were interested in understanding the impact of these methods on different industry sectors.

One key objective was to present an analysis of the current in vitro toxicity testing market in major national markets and its future direction.

REASONS FOR DOING THE STUDY

Classical toxicology testing programs have been in place for many decades now. Over the past 2 decades, ongoing animal welfare activities have spurred the idea of pursuing alternative testing measures in toxicity with minimal pain and suffering to animals. This report aims to identify the key advances in different test categories and the extent of validation by the regulatory authorities. We also were interested in identifying the impact of new technology advancements with possible toxicology applications and also examining their growth potential.

There are different industries that require toxicity testing of their products. Previously, there was broad coverage of these applications. As this market relies strongly on both technology and regulatory forces, this study was aimed to identify the relevance of current developments on pharmaceuticals, chemicals, food additives, cosmetics, and household products.

SCOPE OF REPORT

The study encompasses the major types of traditional toxicity testing methods and the in vitro techniques that have been under review of the Interagency Coordinating Committee for Validation of Alternative Methods (ICCVAM) test methods for toxicity. BCC discusses the two major technology based approaches, mechanistic and nonmechanistic, and determines current market status; examines impact on future markets; and presents forecasts of growth over the next 5 years. Technological issues, including the latest trends, are discussed. Other influential factors such as validation of these alternative measures for toxicity and toxicity testing strategies for chemicals, pesticides, and food additives have also been included. BCC also examines the regulatory role and the different federal and international agencies that play an active role in in vitro toxicology research.

INTENDED AUDIENCE

This report is designed to satisfy the information needs of a wide variety of individuals involved in the toxicity marketplace, including company senior management executives seeking to base their strategic decisions on the latest insights into toxicology market forces and trends. It is also aimed at managers and executives in product research and development and particularly those responsible for bringing new products to market.

METHODOLOGY AND INFORMATION SOURCES

Both primary and secondary research methodologies were used in preparing this study. Primary research includes interviews with leading individuals in relevant companies and associations; primary sources of published data include research studies, company annual reports, and government publications. Secondary sources consist of literature searches, industry journals, and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, critically assessed by BCC.

[buywell2] 13/12/2010 00:25

The thing is old crow Cyprotex have released updates in sept/november for the last 4 years

[old crow] 10/12/2010 10:40

That would be great.

[buywell2] 09/12/2010 22:22

My number 3 choice is going well again , Lipoxen (LPX)



Wonder if Cyprotex have not released a trading update because a buyer is around.

Could explain a few things

[spekky] 07/12/2010 12:31

I see they have re-issued the Cellcyphr news for the US. market (see PRNUS today).....

[spekky] 06/12/2010 12:16

I see Katya is presenting there (p3.1600hrs),there are a lot of prestigious companies represented.Worth a scan if you have time,if only to convince ourselves what a multi-billion dollar market this really is.... :-)

[buywell2] 05/12/2010 23:23

More vacancies equate to more work won.....albeit maybe some in the pipeline

[buywell2] 05/12/2010 23:21

Note

Source BioScience (SBS) my number 2 pick has just made a purchase in Germany which will I believe transform the company.

[buywell2] 05/12/2010 23:19

My take is that Cellumen turnover next year will be more than double that of Apredica prior to the takeover.

'Confirming the success of the cross validation, this client has resumed using CellCiphrTM to identify potential toxicities in its pipeline of drug candidates. In addition, three other clients have also resumed using CellCiphrTM. These include two major pharmaceutical companies and the US Environmental Protection Agency (EPA), where CellCiphrTM has been selected for Phase II participation in the ToxCast™ programme. In addition, a fifth, new client has completed its first CellCiphrTM study.'

[cotton4] 02/12/2010 12:11

The hiring continues - new lab assistant. (Toxicology)

[spekky] 02/12/2010 08:59

Bit of background.Hopefully CellciphrTM will gain some sort of accreditation status in the USA when these studies are complete.

[cotton4] 02/12/2010 08:01

Spekky - I think you're right. Apredica's turnover was some £1m but given that Cellumen was acquired just shortly before CRX bought out Apredica, there was no turnover in the £1m attributable to Cellumen. We now have a product which is generating new income and from large pharma.How much significance can be put on the fact that it is being used by the US EPA, I simply don't know other than CRX now has exposure to the EPA and potentially can promote other products in this direction.

It does, however, demonstrate that they are looking at what has been acquired and targeting any sales potential. IMO this is only the start. 6 months ago CRX had no exposure at all to the TOX market and they appear to be progressing well.Obviously it will take time but the potential is definitely there especially with the increased customer base. If they can build on the number of strategic customers (only one added this year, to the best of my knowledge) then CRX could develop into a sizeable company. 2011 will be a key year, but it would be nice to know how the initial bedding in period has gone. These things are never easy.

[spekky] 01/12/2010 16:49

Slight tick up at the end,I think todays announcement is more significant than the market gives credit for.

[husbod] 01/12/2010 15:44

Too true cotton. Bought some myself this morning only for someone to more or less immediately sell 150k. Hope he/she/it is just about running out!

[cotton4] 01/12/2010 14:39

Husbod - I agree with you. It would seem as though someone is trying to keep the price down. Anytime there has been a buy there has been a similar sell.

[husbod] 01/12/2010 14:37

Thought the announcement might have generated a few more buys but there seems to be a seller on the scene judging by the activity over the last couple of weeks (and today).

[cotton4] 01/12/2010 11:05

I suspect we will get a trading update once there is more visibility re sales going forward. Still in a bedding in period.But todays annoucement is very encouraging.

[husbod] 01/12/2010 10:16

Encouraging

[cotton4] 01/12/2010 08:04

News

December 1, 2010 - CellCiphrTM Toxicity Panels Revalidated by Cyprotex

Cyprotex PLC ("Cyprotex" or the "Company")

Cyprotex (LSE:CRX), the preclinical ADME Tox services company, announces the successful cross validation of the CellCiphrTM cytotoxicity panels and their official relaunch as a Cyprotex service. These panels detect toxicological markers in a range of cell models (HepG2, primary hepatocytes, and cardiomyocytes). This cross validation follows the acquisition of the CellCiphrTM technology from Cellumen, Inc., in August 2010 and its transfer from Cellumen's laboratory to Cyprotex's laboratories.

Cyprotex achieved the cross validation by assessing marketed drugs with known toxicities, and through the participation of a major pharmaceutical company that was an existing client of both Cyprotex and of Cellumen.

Confirming the success of the cross validation, this client has resumed using CellCiphrTM to identify potential toxicities in its pipeline of drug candidates. In addition, three other clients have also resumed using CellCiphrTM. These include two major pharmaceutical companies and the US Environmental Protection Agency (EPA), where CellCiphrTM has been selected for Phase II participation in the ToxCast™ programme. In addition, a fifth, new client has completed its first CellCiphrTM study.

The CellCiphrTM technology Cyprotex acquired from Cellumen applies High Content Screening (HCS) technology to cellular models of disease and toxicity. The technology uses a proprietary advanced informatics and data interpretation platform to assess cytotoxicity to improve prediction of in vivo toxicity. The CellCiphrTM technology is an extensively validated approach that was co-developed with the participation of eight external pharmaceutical and government partners. The CellCiphrTM toxicity profiling panels can reliably identify toxic compounds before entering further preclinical testing.

Drug development failures due to toxicity are a major financial burden to the pharmaceutical industry. These failures are increasingly occurring both in costly late-stage development and, worse, after commercialisation. Identifying potential toxic liabilities at an early stage significantly reduces both the cost of drug development and the need for animal testing.

Commenting on the CellCiphrTM technology, Dr Katya Tsaioun, Cyprotex's Chief Scientific Officer, said: 'Cyprotex's CellCiphrTM technology has been validated by major pharmaceutical companies and selected for use in the EPA's ToxCast™, programme as one of the core technologies in the National Toxicology Program. Our re-validation of this technology is a major milestone in Cyprotex's entry into the in vitro toxicology market that began in August with the acquisition of Apredica in the US, followed by the opening of our new UK toxicology laboratory'.

Dr. Tony Baxter, Cyprotex's Chief Executive Officer, commented: 'Approximately 25% of all spending on drug development is spent on the clinical trials of drugs that fail in those trials due to toxicity. This cost is now the largest source of economic inefficiency in drug development. Looking back, in 1995, 40% of clinical trial failures were due to ADME. But since the adoption of preclinical in vitro ADME, that figure is now below 10%. Cyprotex is at the forefront of applying in vitro technologies to the drug safety problem. Just as Cyprotex's in silico and in vitro ADME services were at the forefront of reducing inefficiencies due to ADME, the Company is now at the forefront of applying the same technologies to the growing problem of toxicity'.

[buywell3] 01/12/2010 00:28

I was expecting a trading statement by now

[old crow] 30/11/2010 09:00

Tempting to buy more 4.60p but no will wait and hope for cheaper

[old crow] 26/11/2010 15:16

buywell and all, any thoughts on OXB could they run out of cash.

[cotton4] 24/11/2010 13:10

New vacancy

Mathematical Modeller

[q1w2e3r4t5] 22/11/2010 12:53

buywell2 : SHP_US